Condition: Bladder Cancer · Sponsor: Cedars-Sinai Medical Center
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
This description comes directly from the study's public registry record.
Charles Rosser, MD · 3104233713 · Charles.rosser@cshs.org
Amy Oppenheimer · 3104233713 · Amy.Oppenheim@cshs.org
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| UCLA | Los Angeles, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| University of Texas Southwestern | Dallas, Texas, United States | Recruiting |
| University of Queensland | Brisbane, Australia | Recruiting |
| Kyoto University | Kyoto, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04564781